Jounce reports updated Phase I/II data for ICOS mAb

Jounce Therapeutics Inc. (NASDAQ:JNCE) reported modest response data in an update from the adaptive, open-label, U.S. Phase I/II ICONIC trial of its inducible T cell co-stimulator (ICOS) agonist mAb JTX-2011 to treat advanced solid tumors. The data were presented at the American Society of Clinical Oncology meeting in Chicago.

Jounce previously reported ICONIC data in an abstract ahead of ASCO (see

Read the full 600 word article

User Sign In